Perpetual Ltd Has $70.47 Million Stake in ADMA Biologics Inc (NASDAQ:ADMA)

Perpetual Ltd trimmed its holdings in shares of ADMA Biologics Inc (NASDAQ:ADMA - Free Report) by 2.2% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,551,813 shares of the biotechnology company's stock after selling 80,864 shares during the period. Perpetual Ltd owned 1.50% of ADMA Biologics worth $70,468,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. Mark Sheptoff Financial Planning LLC bought a new stake in shares of ADMA Biologics during the fourth quarter worth approximately $35,000. Vision Financial Markets LLC bought a new stake in shares of ADMA Biologics during the fourth quarter worth approximately $51,000. Farther Finance Advisors LLC grew its holdings in ADMA Biologics by 1,149.1% during the first quarter. Farther Finance Advisors LLC now owns 2,723 shares of the biotechnology company's stock valued at $53,000 after purchasing an additional 2,505 shares during the period. AlphaQuest LLC acquired a new position in ADMA Biologics during the fourth quarter valued at approximately $84,000. Finally, GF Fund Management CO. LTD. acquired a new position in ADMA Biologics during the fourth quarter valued at approximately $85,000. 75.68% of the stock is owned by institutional investors.

Insider Activity

In other news, Director Steve Elms sold 194,749 shares of the company's stock in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $20.24, for a total value of $3,941,719.76. Following the completion of the transaction, the director owned 87,330 shares in the company, valued at $1,767,559.20. This represents a 69.04% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Lawrence P. Guiheen sold 20,000 shares of the company's stock in a transaction that occurred on Monday, June 9th. The shares were sold at an average price of $20.96, for a total transaction of $419,200.00. Following the completion of the transaction, the director owned 94,830 shares of the company's stock, valued at $1,987,636.80. This trade represents a 17.42% decrease in their position. The disclosure for this sale can be found here. Insiders sold 464,621 shares of company stock worth $9,644,269 over the last quarter. 3.70% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

ADMA has been the subject of a number of analyst reports. Wall Street Zen cut shares of ADMA Biologics from a "hold" rating to a "sell" rating in a report on Friday, May 9th. Cantor Fitzgerald restated an "overweight" rating and set a $25.00 price objective on shares of ADMA Biologics in a report on Tuesday, March 4th. Finally, Raymond James Financial boosted their price objective on shares of ADMA Biologics from $25.00 to $32.00 and gave the company a "strong-buy" rating in a report on Thursday, May 8th.

ADMA Biologics Stock Up 0.3%

Shares of ADMA Biologics stock traded up $0.05 on Monday, hitting $18.21. The company had a trading volume of 4,647,159 shares, compared to its average volume of 3,702,803. The firm has a market capitalization of $4.35 billion, a P/E ratio of 21.42 and a beta of 0.47. ADMA Biologics Inc has a twelve month low of $10.21 and a twelve month high of $25.67. The company has a debt-to-equity ratio of 0.22, a current ratio of 6.58 and a quick ratio of 3.36. The stock has a 50-day moving average of $20.54 and a 200-day moving average of $18.74.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The biotechnology company reported $0.14 earnings per share for the quarter, missing the consensus estimate of $0.16 by ($0.02). The company had revenue of $114.80 million during the quarter, compared to analyst estimates of $116.40 million. ADMA Biologics had a net margin of 45.01% and a return on equity of 47.16%. The firm's quarterly revenue was up 40.2% compared to the same quarter last year. During the same quarter last year, the company earned $0.08 EPS. Research analysts predict that ADMA Biologics Inc will post 0.51 earnings per share for the current year.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.